Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta.

Dong, Z; Greene, G; Pettaway, C; Dinney, C P; Eue, I; Lu, W; Bucana, C D; Balbay, M D; Bielenberg, D; Fidler, I J

Dong, Z; Greene, G; Pettaway, C; Dinney, C P; Eue, I; Lu, W; Bucana, C D; Balbay, M D; Bielenberg, D; Fidler, I J.

Affiliation

Dong Z; Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. zdong@notes.mdacc.tmc.edu

Cancer Res ; 59(4): 872-9, 1999 Feb 15.

Article in En | MEDLINE | ID: mdl-10029078

Subject(s)

Interferon-beta/genetics; Neovascularization, Pathologic/prevention & control; Prostatic Neoplasms/prevention & control; Animals; Cytotoxicity, Immunologic; Gene Transfer Techniques; Genetic Therapy; Humans; Killer Cells, Natural/immunology; Macrophages/immunology; Male; Mice; Mice, Nude; Mice, SCID; Prostatic Neoplasms/blood supply

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Interferon-beta / Neovascularization, Pathologic Limits: Animals / Humans / Male Language: En Journal: Cancer Res Year: 1999 Document type: Article

Search on Google

XML

PubMed Links